Seroprevalence of COVID-19 antibodies among patients living with hemophilia.
Not Applicable
- Conditions
- Health Condition 1: D65-D69- Coagulation defects, purpura and other hemorrhagic conditions
- Registration Number
- CTRI/2022/06/043017
- Lead Sponsor
- Maulana Azad Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with age greater than 13 years diagnosed with Hemophilia
Exclusion Criteria
NO EXCLUSION CRITERIA
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To find out the seroprevalence of COVID-19 antibodies in the patients living with HemophiliaTimepoint: Baseline Cross Sectional
- Secondary Outcome Measures
Name Time Method To find out seroprevalence in previously confirmed cases of COVID-19 patients(detected positive in last 6 month) living with hemophilia.Timepoint: Baseline Cross Sectional;To find out the seroprevalence in asymptomatic patients living with hemophilia and to compare them with the general population (The latest seroprevalence published data at the time of completion of study).Timepoint: Baseline Cross Sectional